These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23471370)

  • 1. Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration.
    Desrosiers NA; Barnes AJ; Hartman RL; Scheidweiler KB; Kolbrich-Spargo EA; Gorelick DA; Goodwin RS; Huestis MA
    Anal Bioanal Chem; 2013 May; 405(12):4067-76. PubMed ID: 23471370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.
    Barnes AJ; Scheidweiler KB; Kolbrich-Spargo EA; Gorelick DA; Goodwin RS; Huestis MA
    Ther Drug Monit; 2011 Oct; 33(5):602-8. PubMed ID: 21860342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.
    Kolbrich EA; Goodwin RS; Gorelick DA; Hayes RJ; Stein EA; Huestis MA
    Ther Drug Monit; 2008 Jun; 30(3):320-32. PubMed ID: 18520604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH.
    Navarro M; Pichini S; Farré M; Ortuño J; Roset PN; Segura J; de la Torre R
    Clin Chem; 2001 Oct; 47(10):1788-95. PubMed ID: 11568088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.
    Hartman RL; Desrosiers NA; Barnes AJ; Yun K; Scheidweiler KB; Kolbrich-Spargo EA; Gorelick DA; Goodwin RS; Huestis MA
    Anal Bioanal Chem; 2014 Jan; 406(2):587-99. PubMed ID: 24232751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.
    Abraham TT; Barnes AJ; Lowe RH; Kolbrich Spargo EA; Milman G; Pirnay SO; Gorelick DA; Goodwin RS; Huestis MA
    J Anal Toxicol; 2009 Oct; 33(8):439-46. PubMed ID: 19874650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations.
    Bowyer JF; Young JF; Slikker W; Itzak Y; Mayorga AJ; Newport GD; Ali SF; Frederick DL; Paule MG
    Neurotoxicology; 2003 Jun; 24(3):379-90. PubMed ID: 12782103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons.
    Mechan A; Yuan J; Hatzidimitriou G; Irvine RJ; McCann UD; Ricaurte GA
    Neuropsychopharmacology; 2006 Feb; 31(2):339-50. PubMed ID: 15999148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions.
    Samyn N; De Boeck G; Wood M; Lamers CT; De Waard D; Brookhuis KA; Verstraete AG; Riedel WJ
    Forensic Sci Int; 2002 Aug; 128(1-2):90-7. PubMed ID: 12208028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans.
    Fallon JK; Kicman AT; Henry JA; Milligan PJ; Cowan DA; Hutt AJ
    Clin Chem; 1999 Jul; 45(7):1058-69. PubMed ID: 10388483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of MDMA and metabolites in human sweat following controlled MDMA administration.
    Barnes AJ; De Martinis BS; Gorelick DA; Goodwin RS; Kolbrich EA; Huestis MA
    Clin Chem; 2009 Mar; 55(3):454-62. PubMed ID: 19168553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of drug incorporation into hair segments and nails by enantiomeric analysis following controlled single MDMA intakes.
    Madry MM; Steuer AE; Hysek CM; Liechti ME; Baumgartner MR; Kraemer T
    Anal Bioanal Chem; 2016 Jan; 408(2):545-56. PubMed ID: 26521178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS.
    Helmlin HJ; Bracher K; Bourquin D; Vonlanthen D; Brenneisen R
    J Anal Toxicol; 1996 Oct; 20(6):432-40. PubMed ID: 8889680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA) in postmortem and antemortem specimens.
    Liu RH; Liu HC; Lin DL
    J Anal Toxicol; 2006 Oct; 30(8):545-50. PubMed ID: 17132249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
    Colado MI; Williams JL; Green AR
    Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).
    Fonsart J; Menet MC; Debray M; Hirt D; Noble F; Scherrmann JM; Declèves X
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):339-47. PubMed ID: 19781562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of MDMA and its metabolites in urine and plasma following a neurotoxic dose of MDMA.
    Valtier S; Phelix CF; Cody JT
    J Anal Toxicol; 2007 Apr; 31(3):138-43. PubMed ID: 17579960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations.
    Mueller M; Yuan J; McCann UD; Hatzidimitriou G; Ricaurte GA
    Int J Neuropsychopharmacol; 2013 May; 16(4):791-801. PubMed ID: 22824226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.